ELI LILLY & Co
Other · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B |
| Operating income | — | — | — | — | — | — |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B |
| Total assets | $112.48B | $78.72B | $64.01B | $49.49B | $48.81B | $46.63B |
| Total liabilities | — | — | — | — | — | — |
| Equity | $26.54B | $14.27B | $10.77B | $10.65B | $8.98B | $5.64B |
| EPS (diluted) | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 | $6.79 |
| Shares out. | 948.2M | 950.2M | 950.3M | 952.3M | 958.4M | 956.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- 31.7%
- Return on equity
- 77.8%
- Return on assets
- 18.4%
- Return on capital (ROCE)
- —
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $27.99
- Revenue growth (YoY)
- 44.7%
- Net income growth (YoY)
- 94.9%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- 3.4%clean
- Piotroski F-Score
- 6/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 good- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Capital Management LlcPassive (13G)May 1, 2026
- Lilly Endowment IncPassive (13G)Apr 20, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Pnc Financial Services Group, Inc.Passive (13G)Feb 7, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Material events
SEC Form 8-K · most recent- Other material eventMay 20, 2026
- Shareholder voteMay 7, 2026
- Results of operationsApr 30, 2026
- Results of operationsFeb 4, 2026
- Director / officer changeNov 21, 2025
- Results of operationsOct 30, 2025
- Other material eventAug 20, 2025
- Results of operationsAug 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (13)
- Dec 9, 2025Tender offercompleted
- Jul 24, 2025Tender offercompleted
- Aug 16, 2024Tender offercompleted
- Dec 26, 2023Tender offercompleted
- Aug 10, 2023Tender offercompleted
- Aug 9, 2023Tender offercompleted
- Nov 30, 2022Tender offercompleted
- Jan 22, 2021Tender offercompleted
- Feb 20, 2020Tender offercompleted
- Feb 15, 2019Tender offercompleted
- Jun 22, 2018Tender offercompleted
- Mar 1, 2017Tender offercompleted
- Nov 1, 2001Tender offercompleted